WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Retrogenix® Non-Human Protein Library. The non-human protein library helps biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species selection..

马萨诸塞州威尔明顿（商业新闻短讯）--Charles River Laboratories International（纽约证券交易所：CRL）今天宣布推出Retrogenix®非人蛋白质文库。非人蛋白质库有助于生物制药客户评估与非人蛋白质组的脱靶结合，以降低体内研究的风险，并有助于非人物种的选择。。

“Developed in-house using the innovative and unique Retrogenix® platform, the new library provides early insights into how therapeutics interact with non-human protein targets in vitro,” said Aidan Synnott, Ph.D., Corporate Vice President, Global Discovery. “These early insights are generated without the lead time and expense associated with ex vivo tissue or in vivo research model studies, allowing clients to progress to safety studies, clinical trials, and IND applications with highly relevant data and increased confidence.”.

全球发现公司副总裁Aidan Synnott博士说：“该新文库是使用创新且独特的Retrogenix®平台在内部开发的，它提供了治疗剂如何在体外与非人蛋白质靶标相互作用的早期见解。”。“这些早期的见解是在没有与离体组织或体内研究模型研究相关的前置时间和费用的情况下产生的，使客户能够以高度相关的数据和增加的信心进入安全性研究，临床试验和IND应用。”。

Confirming whether potential off-targets are conserved across species increases the interpretability of in vivo results and ultimately reduces risk by ensuring safety studies are conducted in an appropriate model from the outset. In addition to offering the non-human protein library, Charles River can also screen observed human off-targets against any suitable non-human homologous proteins to help inform next steps for client drug development..

确认潜在的脱靶是否在物种间保守，可以提高体内结果的可解释性，并通过确保从一开始就在适当的模型中进行安全性研究，最终降低风险。除了提供非人类蛋白质库外，查尔斯河还可以针对任何合适的非人类同源蛋白质筛选观察到的人类脱靶蛋白，以帮助为客户药物开发的下一步提供信息。。

Screening for Off-Target Effects

筛选脱靶效应

The Retrogenix® platform offers the industry’s largest library of human proteins overexpressed in human cells, with over 6,500 human plasma membrane and secreted protein clones, providing a unique screening tool for discovering primary target receptors and reliably assessing potential off-target binding issues.

Retrogenix®平台提供了业界最大的人类细胞中过表达的人类蛋白质库，拥有6500多个人类质膜和分泌的蛋白质克隆，为发现主要靶受体和可靠评估潜在的脱靶结合问题提供了独特的筛选工具。

With the new non-human protein library, Charles River is building on the Retrogenix® platform’s established technology, helping clients ensure they have the right models selected prior to beginning in vivo studies, saving time and helping deliver safer, more effective drugs..

通过新的非人类蛋白质库，Charles River正在Retrogenix®平台的既定技术基础上进行构建，帮助客户确保在开始体内研究之前选择正确的模型，节省时间并帮助提供更安全，更有效的药物。。

Off-target screening is an established part of the IND submission process, and is traditionally performed using tissue cross reactivity (TCR) studies. Data from the Retrogenix® platform has become an established complementary or alternative data point across multiple modalities, therapeutic areas, and with international regulatory agencies..

脱靶筛选是IND提交过程的既定部分，传统上使用组织交叉反应（TCR）研究进行。来自Retrogenix®平台的数据已成为跨多种模式，治疗领域以及国际监管机构的既定补充或替代数据点。。

Driving Innovation in the 3Rs

推动3R创新

Designed in silico and synthetically generated, the biosynthetic non-human protein library incorporates important tenants of the 3Rs—reduction and refinement—leveraging technological innovations to responsibly progress research.

生物合成非人蛋白质文库采用计算机设计和合成生成，结合了3Rs减少和改进的重要租户，利用技术创新负责任地推进研究。

“The integration of the Retrogenix® Non-Human Protein Library into our drug discovery portfolio enhances the precision and effectiveness of lead candidate selection,” added Professor Julie Frearson, Ph.D., Corporate Senior Vice President & Chief Scientific Officer. “Technology is a cornerstone of innovation, and as we continue to drive forward change in drug development, these innovations allow us to refine our use of research models while supporting the discovery of novel medicines.”.

“将Retrogenix®非人类蛋白质文库整合到我们的药物发现组合中，提高了主要候选人选择的准确性和有效性，”公司高级副总裁兼首席科学官Julie Frearson教授补充道。“技术是创新的基石，随着我们继续推动药物开发的变革，这些创新使我们能够改进研究模型的使用，同时支持新药的发现。”。

Building on the imperative to deliver on the 3Rs (Replacement, Reduction, and Refinement of research animals), Charles River launched the Alternative Methods Advancement Project (AMAP), with a dedicated pursuit of scientific and technological innovation and by aligning the Company’s strategic efforts with the focus needed to advance animal alternatives..

基于实现3R（研究动物的替代，减少和改进）的必要性，Charles River启动了替代方法推进项目（AMAP），致力于科技创新，并将公司的战略努力与推进动物替代品所需的重点相结合。。

About the Alternative Methods Advancement Project (AMAP)

关于替代方法推进项目（AMAP）

The Alternative Methods Advancement Project (AMAP) is a Charles River initiative dedicated to developing alternatives to reduce the use of animals in testing. As we enter the next frontier of drug development, AMAP will facilitate strategic and purposeful investing to lead the way toward a future where more patients receive needed treatments and medicines safely, swiftly, and successfully.

替代方法改进项目（AMAP）是查尔斯河倡议，致力于开发替代方法，以减少测试中动物的使用。随着我们进入药物开发的下一个前沿，AMAP将促进战略性和有目的的投资，以引领更多患者安全，快速，成功地接受所需治疗和药物的未来。

In keeping with our commitment to the 3Rs, we are dedicated to pursuing scientific and technological innovations to explore new and exciting ways we can further reduce the use of animals in testing. The guidance of AMAP will help us align our investments, partnerships, product and service initiatives, and advocacy efforts as we focus on our goal of investing $300 million over the next five years to further enhance this critical mission and drive industry-wide adoption of alternatives..

根据我们对3R的承诺，我们致力于追求科学和技术创新，以探索新的和令人兴奋的方法，我们可以进一步减少动物在测试中的使用。AMAP的指导将帮助我们调整我们的投资、合作伙伴关系、产品和服务计划以及宣传工作，因为我们专注于在未来五年投资3亿美元的目标，以进一步加强这一关键任务，并推动全行业采用替代方案。。

About Charles River

关于Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

Charles River提供重要的产品和服务，以帮助制药和生物技术公司、政府机构和全球领先的学术机构加速其研究和药物开发工作。我们敬业的员工专注于为客户提供他们所需要的，以改进和加速为需要的患者发现、早期开发和安全制造新疗法。